uniQure N.V. $QURE Shares Newly Acquired by Privium Fund Management B.V.

Key Points

• Privium Fund Management opened a new uniQure position, buying 216,197 shares worth about $5.22 million. The stake represented 0.31% of uniQure and 1.0% of the fund’s portfolio.
• uniQure shares rose 3.3% to $21.70 in Friday trading. For its latest quarter, the company reported a smaller-than-expected loss per share, but revenue of $5.20 million fell short of the $6.17 million consensus estimate.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $56.83; views range from one Sell to eleven Buy ratings.

Privium Fund Management B.V. acquired a new position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 216,197 shares of the biotechnology company's stock, valued at approximately $5,223,000. uniQure comprises 1.0% of Privium Fund Management B.V.'s investment portfolio, making the stock its 22nd biggest holding. Privium Fund Management B.V. owned about 0.31% of uniQure as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP bought a new stake in shares of uniQure during the second quarter worth approximately $15,254. IFP Advisors Inc lifted its holdings in uniQure by 39.8% in the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company's stock valued at $128,000 after buying an additional 791 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in uniQure in the third quarter valued at approximately $86,000. Fulton Bank N.A. bought a new position in uniQure in the second quarter valued at approximately $220,000. Finally, Activest Wealth Management bought a new position in uniQure in the third quarter valued at approximately $121,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Trading Up 3.3%

NASDAQ QURE traded up $0.69 during trading on Friday, reaching $21.70. 1,172,882 shares of the stock traded hands, compared to its average volume of 1,937,432. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $51.72. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -6.18 and a beta of 1.14. The stock's 50-day moving average price is $31.86 and its 200 day moving average price is $29.68.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The company had revenue of $5.20 million for the quarter, compared to analyst estimates of $6.17 million. Analysts predict that uniQure N.V. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on QURE. Royal Bank Of Canada dropped their target price on shares of uniQure from $65.00 to $48.00 and set an "outperform" rating for the company in a research report on Friday, October 2nd. William Blair upgraded uniQure to a "strong-buy" rating in a research report on Wednesday, September 23rd. UBS Group started coverage on uniQure in a research note on Thursday, October 15th. They set a "buy" rating and a $48.00 price objective for the company. Wolfe Research upgraded uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective for the company in a report on Wednesday, July 29th. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $75.00 target price on shares of uniQure in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $56.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure's best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.